Metabolites of intestinal fora can be used as diagnostic and progressive markers for mild cognitive impairment

Purpose: The aim of the work was to analyze the metabolites of the intestinal microbiota from patients with mild cognitive impairment (MCI) due to Alzheimer's disease and progressive MCI due to Alzheimer's disease. Method: Two cohorts were established. The first one included 87 subjects with 30 healthy controls (NC), 22 patients with MCI due to Alzheimer's disease, and 35 patients with Alzheimer's disease (AD). The second cohort included 87 patients with MCI due to Alzheimer's disease, who were followed up for 2 years, and finally were divided into progressive MCI due to Alzheimer's disease group (P-G) and unprogressive MCI due to Alzheimer's disease group (U-G) according their cognitive levels. Fecal samples were collected from all patients at the baseline time point. Differential metabolites were subjected to pathway analysis by MetaboAnalyst. Results: In the first cohort, we found 21 different metabolites among the three groups (AD, MCI, and NC). In the second cohort, we identified 1..., , , # Metabolites of intestinal fora can be used as diagnostic and progressive markers for mild cognitive impairment In this study, we assessed the cognition of 87 community-dwelling elderly individuals aged 65 or older. Based on the degree of cognitive impairment, they were divided into three groups: 35 individuals with Alzheimer's disease (AD), 22 individuals with mild cognitive impairment (MCI), and 30 individuals with normal cognitive function. Demographic data including gender, age, education level, smoking status, and alcohol consumption were collected at baseline. Additionally, fecal samples were collected from all patients for analysis of serum levels of P-tau181, NF-light, Aβ1-42, Aβ1-40 and GFAP. Blood cells were also collected for APOE genotype testing. Furthermore, metabolites in the gut microbiota were analyzed through fecal sample testing. Subsequently, a two-year follow-up was conducted to assess cognitive function in these groups. Participants were categorized as either p...研究目的：本研究旨在分析阿尔茨海默病源性轻度认知障碍（Mild Cognitive Impairment, MCI）以及阿尔茨海默病源性进展性轻度认知障碍患者的肠道菌群代谢物。 研究方法：本研究设立两个队列。第一队列共纳入87名受试者，包括30名健康对照者（Normal Control, NC）、22名阿尔茨海默病源性轻度认知障碍患者以及35名阿尔茨海默病（Alzheimer's Disease, AD）患者。第二队列共纳入87名阿尔茨海默病源性轻度认知障碍患者，对其进行为期2年的随访，最终根据认知水平分为阿尔茨海默病源性进展性轻度认知障碍组（P-G组）与阿尔茨海默病源性非进展性轻度认知障碍组（U-G组）。所有受试者均在基线阶段采集粪便样本，通过MetaboAnalyst软件对差异代谢物进行通路分析。 研究结果：第一队列中，我们在AD、MCI与NC三组间筛选出21种差异代谢物。第二队列中，我们共鉴定出1..., , , # 肠道菌群代谢物可作为轻度认知障碍的诊断及进展标志物 本研究对87名65岁及以上的社区居住老年人进行认知功能评估。根据认知损害程度将其分为三组：35名阿尔茨海默病（AD）患者、22名轻度认知障碍（MCI）患者以及30名认知功能正常者。基线阶段收集受试者的人口统计学资料，包括性别、年龄、受教育程度、吸烟史与饮酒史。同时采集所有受试者的粪便样本，以检测血清P-tau181、NF-light、Aβ1-42、Aβ1-40及GFAP水平；采集血细胞样本进行APOE基因型检测；此外，通过粪便样本分析肠道菌群代谢物。随后对上述受试者进行为期2年的随访，评估其认知功能，将参与者分为……